20221027104337.jpg)
According to updated findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery continues to significantly improve disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene mutations.
The National Cancer Institute has awarded a UM1 grant renewal to Yale Cancer Center. The 6-year, $3 million a year grant will fund early phase investigator-initiated clinical trials to develop new potential therapies for treating both solid tumors and hematologic malignancies.
Marcella Nunez-Smith, MD, MHS, has been appointed Director of the Center for Community Engagement and Health Equity for Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH), as well as Chief Health Equity Officer & Deputy Chief Medical Officer, at SCH, and Associate Cancer Center Director for Community Outreach and Engagement at YCC.
Yale Cancer Center researchers were awarded a $11 million grant renewal from the National institutes of Health to fund the Yale Specialized Program of Research Excellence (SPORE) in Lung Cancer.
Markus Müschen, M.D., Ph.D., has been named the inaugural Director of the Center of Molecular and Cellular Oncology at Yale Cancer Center and Smilow Cancer Hospital. Müschen will also be appointed Arthur H. and Isabel Bunker Professor of Medicine (Hematology) and Professor of Immunobiology at Yale School of Medicine.
In a new study by Yale Cancer Center, researchers have demonstrated that in states with expanded Medicaid coverage through the Affordable Care Act (ACA) a higher percentage of women with breast cancer had their disease diagnosed at an early stage. No such change was seen in states that didn’t expand their coverage. The findings were published today in JAMA Surgery.
New findings led by Yale Cancer Center researchers and experts across several medical specialties at Yale identify a leading mechanism behind the pathophysiology of Covid-19 and pinpoint a biological marker for the mechanism that may aid in treating these patients.
Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer.
Yale Cancer Center scientists have developed a new cell screening method for agents that alter biologic functions. This approach uses thousands of artificial proteins called “traptamers” and may help to answer research questions that are difficult to address with other cell screening methods, including the SARS-CoV-2 virus, COVID-19. The data is published today in the journal Cell Reports.
Yale Cancer Center scientists have identified mutations in metabolite-producing genes as a disruption of DNA repair. These mutation-driven “oncometabolites” may make cells more prone to developing cancer—but also more vulnerable to new cancer treatment strategies.
Results of a Phase I clinical trial conducted by researchers at the Yale Cancer Center have shown that ARV-110, an androgen receptor PROTAC® protein degrader, demonstrates anti-tumor responses in patients with metastatic castration-resistant prostate cancer.
According to findings led by researchers at Yale Cancer Center, treatment with the targeted therapy osimertinib following surgery significantly improves disease-free survival (DFS) in patients with early-stage, non-small cell lung cancer (NSCLC) with EGFR gene mutations.
The common belief that tumors arise via activation of a few genes that “drive” cancer development is unsupported by a widespread investigation into those genes and others in three large patient genetic databases, according to a study led by Yale Cancer Center (YCC) researchers.
A new study led by Yale Cancer Center (YCC) researchers shows women with high-risk HER2-negative breast cancer treated before surgery with immunotherapy, plus a PARP inhibitor with chemotherapy, have a higher rate of complete eradication of cancer from the breast and lymph nodes compared to chemotherapy alone.
Yale Cancer Center announces the appointments of Thomas Prebet, M.D., Ph.D., as Disease Aligned Research Team (DART) Leader for Myeloid Malignancies and Amer Zeidan, MBBS, as Director of the Hematology Early Therapeutics Program.
A new study led by Yale Cancer Center (YCC) researchers has demonstrated in mice that hormones released from the pancreas itself can advance pancreatic cancer — and that weight loss can stop this process in its early stages. The research was published today in the journal Cell.
Researchers at Yale Cancer Center (YCC) have found that use of the checkpoint inhibitor pembrolizumab can extend life with very few side effects in this patient population.
There are substantial costs associated with breast cancer screenings for U.S. women in their 40s, a new Yale Cancer Center-led study finds, and these costs vary widely by region.
Mehra Golshan, M.D., M.B.A., F.A.C.S., has been appointed the inaugural Deputy Chief Medical Officer for Surgical Services at Smilow Cancer Hospital and Yale Cancer Center, Professor of Surgery at Yale School of Medicine, and Interim Director of the Breast Center at Smilow Cancer Hospital.
According to the results of a large, global study led by Yale Cancer Center researchers, even a tiny amount of a biomarker known as PD-L1 (programmed death-ligand1) can predict a long-term survival benefit from using pembrolizumab (Keytruda).
Raymond Lenox, APRN, was presented with the Yale Cancer Center Ruth McCorkle Oncology Advanced Practice Provider Award at YCC’s annual Conclave.
Qin Yan, Ph.D., was presented with the Yale Cancer Center (YCC) Class of 1961 Cancer Research Award at YCC’s annual Conclave
Yale Cancer Center (YCC) held its annual Conclave and award ceremony. The night celebrated the accomplishments of goals set for 2019 and honored faculty and staff with clinical and research prizes.
Debra Brandt, D.O. and Kevin Kim, M.D. were each honored with the Yale Cancer Center (YCC) Award for Clinical Excellence at YCC’s annual Conclave on Monday, January 13.
Tara Sanft, M.D., associate professor of Medicine (Medical Oncology) and Director of the Smilow Cancer Hospital (SCH) Survivorship Clinic, has been appointed the inaugural Chief Patient Experience Officer at Yale Cancer Center (YCC) and SCH at Yale New Haven Hospital.
Sarah Mougalian, M.D., assistant professor of Medicine (Medical Oncology) has been named the inaugural Deputy Chief Ambulatory Officer at Smilow Cancer Hospital (SCH) at Yale New Haven Hospital.
Yale Cancer Center (YCC) announces the launch of the Center for Community Engagement and Health Equity (CEHE). Building on YCC’s longstanding commitment to high-quality, expert, and patient-centered cancer care, screening, and prevention across the state of Connecticut, the new Center is dedicated to ensuring cancer health equity and improving outcomes with an emphasis on traditionally underserved neighborhoods.
The U.S. Food & Drug Administration (FDA) granted accelerated approval to the drug enfortumab vedotin (EV) to treat adult patients with advanced urothelial or bladder cancer.
In a clinical trial led by Yale Cancer Center (YCC) and Smilow Cancer Hospital, researchers aim to exploit DNA mutations in the treatment of two blood and bone marrow cancers, a different tacit than the more traditional approach of blunting or switching off genetic mutations linked to cancer
New findings by Yale Cancer Center (YCC) and Smilow Cancer Hospital researchers show that as the use of the drug ibrutinib climbs in patients with chronic lymphocytic leukemia (CLL), so do the rates of patients who stop taking the drug.
A new study by Yale Cancer Center (YCC) researchers shows understanding treatment patterns for patients with acute myeloid leukemia (AML) is vital to develop strategies to improve outcomes.
A new study by Yale Cancer Center (YCC) and Smilow Cancer Hospital researchers suggests that the drug venetoclax aids therapy for relapsed/refractory myelodysplastic syndromes, especially when paired with azacytidine.
Identifying the type of pain an adult with sickle cell disease (SCD) experiences may be useful in improving treatment, according to a new study by researchers at Yale Cancer Center (YCC) and Smilow Cancer Hospital.
Roy Herbst, M.D., Ph.D., chief of Medical Oncology at Smilow Cancer Hospital, has been researching lung cancer and treating patients with the disease for more than 25 years. He discusses the facts about lung cancer, ways to reduce your risk, and how new treatments are significantly extending life for patients.
The checkpoint inhibitor pembrolizumab (Keytruda) offers patients with advanced head and neck cancers longer survival time, according to a new global study led by Yale Cancer Center (YCC).
Yale Cancer Center scientists have built a powerful genomic research platform to study cervical cancer, a disease that often is untreatable if it progresses after surgery or primary chemo-radiation treatment.
According to new findings by Yale Cancer Center scientists, higher levels of genetic mutations in a tumor biopsy are linked to improved clinical outcomes in patients using pembrolizumab (Keytruda) to treat non-small cell lung cancer (NSCLC).
Yale Cancer Center (YCC) scientists presented research at the 61st annual American Society for Radiation Oncology (ASTRO) annual meeting in Chicago.
The results of a phase II clinical trial by Yale Cancer Center (YCC) researchers show adding high-dose radiation after immunotherapy stops working increases survival time for patients with metastatic non-small-cell lung cancer (NSCLC).
A team of investigators at Yale Cancer Center (YCC) have found a major chink in the armor of an incurable childhood brain cancer called Diffuse Intrinsic Pontine Gliomas (DIPG).
There are no approved treatment options for patients with advanced bladder cancer after standard chemotherapy and immune treatments, but the results of a phase II clinical trial led by Yale Cancer Center and Smilow Cancer Hospital researchers demonstrates an effective treatment for this deadly disease.
In a new study, Yale Cancer Center scientists have demonstrated a powerful method to analyze how tumor cells are altered as they metastasize to the brain.
Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH) are proud to announce a five-year grant awarded by The Frederick A. DeLuca Foundation to establish The DeLuca Center for Innovation in Hematology Research.
One of the most promising new generations of cancer treatment called Chimeric Antigen Receptor (CAR) T-cell therapy is now available for patients at Smilow Cancer Hospital. CAR T-cell therapy is groundbreaking immunotherapy that can cure patients with certain blood cancers who have run out of treatment options.
Yale Cancer Center researchers have identified a potential therapy that combines two types of molecularly targeted drugs to produce a synergistic effect against head and neck cancer.
In a new study by Yale Cancer Center (YCC), scientists suggest that as the number of clinical trials in cancer immunotherapy grows exponentially, some caution should be exercised as we continue to better understand the biology of these new therapeutic targets.
When melanoma turns metastatic, it spreads to the brain in more than 40% of patients. Published today in the Journal of Clinical Oncology (JCO), a study by Yale Cancer Center researchers show a checkpoint inhibitor immunotherapy drug has meaningful benefit for these patients.
Branding matters when it comes to choosing a hospital, according to a new novel study by Yale Cancer Center (YCC) researchers published in the journal Annals of Surgical Oncology.
U.S. and European guidelines on treating Polycythemia Vera (PV), a potentially deadly blood cancer, call for two treatments for patients with high-risk disease: therapeutic phlebotomy and cytoreductive therapy with a drug called hydroxyurea (HU). HU is the most commonly used option, but evidence for HU treatment is limited and both treatments are underused. Now, researchers at Yale Cancer Center have documented reduced risk of death and incidence of blood clots in patients receiving those therapies.
Antonio Omuro, M.D., has been appointed the new Chief of Neuro-Oncology and a Leader for the Brain Tumor Program at Yale Cancer Center (YCC) and Smilow Cancer Hospital.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right